Real-world prognosis of eyes with diabetic macular oedema receiving treatment with vascular endothelial growth factor (VEGF) inhibitors

This is a protocol for a Cochrane Review (prognosis). The objectives are as follows:

To assess one- to five-year visual prognosis of eyes receiving intravitreal VEGF inhibitor treatments for DMO in routine clinical practice.

Investigation of sources of heterogeneity between studies

We will assess the source of heterogeneity in the outcome measures between studies.

This is a protocol.

Health topics:

Endocrine & metabolic > Diabetes > Diabetic eye disease

Published:

21 October 2021

Authors:

Bhandari S, Nguyen V, Fraser-Bell S, Di Tanna GL, Gillies MC

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Bhandari S, Nguyen V, Fraser-Bell S, Di Tanna GL, Gillies MC. Real-world prognosis of eyes with diabetic macular oedema receiving treatment with vascular endothelial growth factor (VEGF) inhibitors (Protocol). Cochrane Database of Systematic Reviews 2021, Issue 10. Art. No.: CD015030. DOI: 10.1002/14651858.CD015030.